Synergistic Cell-Targeting Systems

The present inventive concept integrates Shiga toxin effector polypeptides with distinct technologies such as AI, IoT, blockchain, and nanomaterials to create novel, more powerful systems for targeted conjugation and personalized medicine.

The original patent disclosed cell-targeting molecules with Shiga toxin effector polypeptides, but these molecules had limitations in terms of tracking, optimization, and delivery. The new inventive concept addresses these limitations by incorporating synergistic combinations of technologies to enhance the efficacy and versatility of cell-targeting molecules.

The new inventive concept comprises systems and methods that integrate Shiga toxin effector polypeptides with AI-powered optimization algorithms, blockchain-based tracking modules, IoT-based sensor networks, and nanomaterial-based delivery systems. These combinations enable real-time monitoring of target biomolecule binding, personalized medicine, and targeted release of therapeutic agents. For example, the system of claim 1 integrates a cell-targeting molecule with a blockchain-based tracking module, allowing for secure and transparent monitoring of target biomolecule binding. The method of claim 2 utilizes an AI-powered optimization algorithm to select target biomolecules for a cell-targeting molecule, ensuring optimal efficacy.

The new claims introduce novel and non-obvious combinations of Shiga toxin effector polypeptides with distinct technologies, providing a synergistic effect that enhances the functionality and versatility of cell-targeting molecules. The inventive step lies in the recognition of the potential benefits of integrating these technologies and the development of systems and methods that realize these benefits.

Alternative embodiments of the inventive concept could include the use of different AI algorithms, blockchain platforms, or nanomaterials. Variations could also include the integration of additional technologies, such as CRISPR gene editing or quantum computing, to further enhance the functionality of cell-targeting molecules.

The inventive concept has significant commercial potential in the fields of personalized medicine, targeted therapy, and biomedical research. The integration of AI, IoT, blockchain, and nanomaterials could lead to the development of novel therapeutic agents, diagnostic tools, and research platforms, addressing a market estimated to be worth billions of dollars.